Hanmi Pharmaceutical 1.8 trillion-won technology transfer prompts broker price-target hikes; Hyundai Motor collaboration takes shape

Hanmi Pharmaceutical shares rose for a second consecutive day as news related to a technology transfer emerged. A securities firm report raised the company’s target price, positively assessing its research and development results. The technology export achievement was cited in the market as evidence of its R&D competitiveness.

Reports said Hanmi Pharmaceutical had 1.8 announced news of a technology transfer agreement worth trillion won. Its shares continued to rise after the news. Announcements from the company and securities firms came at the same time.

Hyundai Motor said its collaboration with Boston Dynamics had entered a more concrete phase. Reflecting expectations for the collaboration, a securities firm set Hyundai Motor’s target price at 100 ten thousand won. The collaboration was reported to involve the robotics business.

Hyundai Mobis received positive assessments of the outlook for its actuator business. Securities firms raised their target prices in related reports. Actuators were cited as one of the electrification components.

Hyundai Motor and Kia's 5monthly sales results were mixed. Hyundai Motor was reported to have faced constraints on its results due to supply issues affecting some parts. Kia's monthly results improved on strong sales of eco-friendly vehicles.

Samsung Securities is holding a stock-gifting event for new customers. The stocks to be given away were identified as Samsung Electronics, Hyundai Motor, and Doosan Enerbility. The company announced that the event applies to customers who open an account and meet the requirements.